Mercado de biológicos en México

Overview of the Biologicals Market in Mexico:

The biologics market in Mexico reached USD 6,082.6 million in 2025. Looking ahead, IMARC Group expects the market to reach USD 11,201.9 million by 2034 , exhibiting a compound annual growth rate (CAGR) of 6.81% during 2026–2034 . Advancements in cold chain logistics and distribution, including modernized storage facilities and temperature-controlled transportation, are improving the accessibility of biologics in Mexico. Furthermore, government healthcare modernization efforts, such as improving public health services, adopting digital technologies, and expanding access in rural areas, are facilitating greater adoption of biologics. These initiatives ensure timely and efficient biologic treatments nationwide, increasing the market share of biologics in Mexico and improving healthcare delivery across the country.

Trends in the Mexican Biologicals Market:

Greater attention to the modernization of healthcare systems

The advancement of Mexico's healthcare system is a crucial factor for the growth of the biologics market, with recent reforms focused on improving infrastructure and expanding access to sophisticated medical treatments. In particular, the governing body is improving public health services and integrating digital health technologies to enhance patient care and coordination, thereby increasing access to biologics. The implementation of electronic health records (EHRs) and telemedicine platforms is enabling healthcare professionals to optimize care, ensuring that patients can access biologic therapies in a timely manner, even in remote areas. In 2024, President Claudia Sheinbaum announced five key health initiatives aimed at further modernizing the system, with implementation slated for 2025. The strategy included initiatives to expand vaccination efforts, modernize hospitals, strengthen the IMSS-Bienestar program, optimize drug distribution networks, and standardize access to healthcare throughout Mexico, with a special emphasis on underserved and rural communities. These changes aim to close the healthcare gap and improve access to biologic therapies, ensuring that biologics are included in treatment plans nationwide. As the healthcare system continues to evolve, these initiatives are expected to significantly improve the acceptance and market penetration of biologics, making them more accessible to Mexico's diverse population. The ongoing development of the healthcare sector is vital to fostering the development of biologic treatments in both urban and rural areas.

Advances in cold chain logistics and distribution

Improvements in cold chain logistics and distribution are significantly increasing the availability of biologics in Mexico, particularly those requiring strict temperature control during transport and storage. With the growing demand for biologic therapies, an initiative is underway to improve the infrastructure necessary for the safe and effective delivery of these treatments. Upgrading cold storage systems, temperature-controlled transport, and improving control technologies are crucial to ensuring that biologics reach healthcare facilities across the country in optimal condition. These improvements reduce the risk of biodegradation that can occur due to inadequate temperature management, thus guaranteeing a more stable and reliable supply of these essential medicines. A prime example of this shift is UPS Healthcare's planned introduction of new cold chain facilities in Mexico City in 2025. These IATA CEIV Pharma-certified facilities are specially designed to handle temperature-sensitive pharmaceutical shipments, accommodating products from ambient to frozen temperatures. This advancement not only highlights the growing importance of temperature-sensitive logistics within the biologics sector but also demonstrates how international logistics companies are investing resources to ensure the safe and rapid delivery of biologics. As these facilities grow and develop, they will enhance Mexico's capacity to distribute biologics efficiently, guaranteeing broader access to these essential therapies throughout the country. These improvements are critical to driving the growth of the biologics market in Mexico, ensuring that biologic therapies reach more patients with greater reliability and efficiency.

Segmentation of the Biologicals Market in Mexico:

The IMARC Group offers an analysis of key trends in each market segment, along with national and regional forecasts for 2026-2034. Our report has categorized the market based on source, product, disease, and manufacturing.

Fuente Insights:

• Microbial
• Mammal
• Others

The report offers a detailed breakdown and analysis of the market based on the source. This includes Microbial, Mammalian, and others.

Product insights:

• Monoclonal antibodies
• Vaccines
• Recombinant proteins
• Antisense, RNAi and molecular therapy
• Others

The report also provides a detailed breakdown and analysis of the market by product. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense antibodies, RNAi and molecular therapies, and others.

Disease Insights:

• Oncology
• Immunological disorders
• Cardiovascular disorders
• Hematological disorders
• Others

El informe ofrece un desglose y un análisis detallados del mercado en función de la enfermedad. Esto incluye oncología, trastornos inmunológicos, trastornos cardiovasculares, trastornos hematológicos y otros.

Insights de fabricación:

• Externalizado
• Interno

El informe también ofrece un desglose y un análisis detallados del mercado en función de la fabricación. Esto incluye la Externalizado y la interno.

Insights regionales:

• Norte de México
• México Central
• Sur de México
• Otros

El informe también ha proporcionado un análisis exhaustivo de los principales mercados regionales, que incluyen el norte de México, el centro de México, el sur de México y otros.

Panorama competitivo:

El informe de investigación de mercado también ha proporcionado un análisis exhaustivo del panorama competitivo. El informe incluye análisis de la competencia como la estructura del mercado, el posicionamiento de los actores clave, las principales estrategias ganadoras, el cuadro de mando de la competencia y el cuadrante de evaluación de las empresas. También se ofrecen perfiles detallados de las principales empresas.

Noticias del México Biológicos Mercado:

• En febrero de 2024, La COFEPRIS de México anunció un plan estratégico de desarrollo de biosimilares para impulsar la producción local y la seguridad reglamentaria. El plan incluye dos unidades de expertos para agilizar las aprobaciones y fomentar la colaboración de la industria. Los analistas sanitarios lo consideran un modelo regional con posibles beneficios económicos y para la salud pública a largo plazo.

Cobertura del México Biológicos Mercado:

Preguntas clave respondidas en este informe:

• ¿Cómo se ha comportado hasta ahora el mercado biológico mexicano y cómo se comportará en los próximos años?
• ¿Cuál es el desglose del mercado mexicano de productos biológicos en función de su origen?
• ¿Cuál es la distribución del mercado de productos biológicos en México por productos?
• What is the distribution of the biological products market in Mexico by disease?
• What is the breakdown of the Mexican market for biological products based on manufacturing?
• What is the breakdown of the Mexican market for biological products by region?
• What are the different stages of the value chain in the biological products market in Mexico?
• What are the main driving factors and challenges in the biological products sector in Mexico?
• What is the structure of the biological products market in Mexico and who are its main players?
• What is the level of competition in the Mexican biologics market?

Main benefits for stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and market dynamics for biologics in Mexico from 2020 to 2034.
• The research report provides the latest information on market drivers, challenges, and opportunities in the biological products market in Mexico.
• Porter's Five Forces analysis helps stakeholders assess the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within Mexico's biotechnology industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of the major market players.